Rexahn Pharma (RNN) Reports Q1 Loss of $0.02
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Rexahn Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update
May 9, 2016 9:01 AM EDTProgresses Novel Targeted Anti-Cancer Therapies in Clinical Development
 Initiates Phase Ib/IIa Clinical Trial of RX-3117 and Begins Enrollment in Phase IIa Randomized Clinical Trial of Archexin®
ROCKVILLE, Md., May 09, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced financial results for the first quarter ended March 31, 2016 and provided an update on the Companys clinical development programs.
Rexahn... More
